long intergenic non-protein coding RNA 1817Genealiases: []
Q-omics provides the consensus-scored LINC01817 profile across patient tissues and cancer cell-line models. LINC01817 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LINC01817 is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, LINC01817 RNA expression shows 6,254 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, LUSC, and STAD as cancer lineages where LINC01817 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01817 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01817 survival associations across molecular data types. LINC01817 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01817 RNA expression–survival associations across cancer types. High LINC01817 expression shows unfavorable associations in KICH, OV, CESC, ACC, LUSC and LUAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for LINC01817 RNA expression.
This table summarizes LINC01817 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01817. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01817 shows lower tumor expression in LUSC, LUAD, LIHC and PRAD. The LUSC box plot shows higher LINC01817 RNA expression in normal versus tumor tissue (log2 FC = −0.078, t-test p < 0.001).
This table shows molecular features associated with LINC01817 in patient tissues and cancer cell lines. In patient samples, LINC01817 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
